Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13213485 | 0.92 | MAPKAPK2 (0.58) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL13213670 | 0.92 | MAPKAPK2 (0.58) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL3015203 | 0.86 | MAPKAPK2 (0.47) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL13213948 | 0.84 | FLT3 (0.44) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL3024265 | 0.84 | MAPK8 (0.48) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL13213636 | 0.84 | MAPKAPK2 (0.52) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL3022411 | 0.83 | CDK2 (0.43) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL3011533 | 0.83 | MAPKAPK2 (0.51) | MAPKAPK2CDK2CCNE1FLT3MAPK8 | |
| SCHEMBL3022446 | 0.81 | MAPKAPK2 (0.36) | MAPKAPK2CDK2CCNE1FLT3SYK | |
| SCHEMBL3022048 | 0.81 | FLT3 (0.45) | MAPKAPK2CDK2CCNE1FLT3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | MAPKAPK2 23/4885CDK2 40/4885CCNE1 468/4885 |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | MAPKAPK2 24/4885CDK2 67/4885CCNE1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.